August 17, 2005 Access Pharmaceuticals jumped up more than 50% after revealing that it may sell non-core assets to address a near-term cash crisis, Momenta was higher on news that it will seek approval this month for its generic form of Lovenox, Abbott can keep its controversial weight-loss drug on the market, Genentech and Biogen Idec asked the FDA for approval of Rituxan as a first-line treatment, EntreMed won two patents for its cancer drug, and Structural GenomiX began enrollment in a Phase II/III trial of a leukemia drug. After spending much of the day in positive territory, the Centient Biotech 200™ succumbed to late-day pressure, closing with a 7 point loss at 3717.55, a drop of .19%. More details...
